Tyra Biosciences' Q1 net loss widens on higher R&D costs
U.S. RESEARCH ROUNDUP-Autodesk, Citigroup, Wells Fargo
Brief: Tyra Biosciences Agreed To Issue 4 Million Shares At $31.50 Per Share To A Large Investment Management Firm - SEC Filing
Tyra Biosciences Q4 net loss widens on higher R&D costs
U.S. RESEARCH ROUNDUP-Brixmor Property, Mohawk Industries, UDR
U.S. RESEARCH ROUNDUP-Adobe, Exxon Mobil, Stellar Bancorp
Brief: Tyra Biosciences Strengthens Leadership Team With Appointments Of Bhavesh Ashar As Chief Operating Officer And Heather Faulds As Chief Regulatory Officer
Tyra Biosciences Q3 net loss widens
Tyra Biosciences Q2 net loss widens to $28.1 mln
Tyra Biosciences Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Tyra Biosciences Doses First Patient In Phase 2 Study Of Tyra-300 In Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (Surf302)
Tyra Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Tyra Biosciences Inc Files For Mixed Shelf Of Up To $500 Million - SEC Filing
Tyra Biosciences Inc expected to post a loss of 49 cents a share - Earnings Preview
Tyra Biosciences Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: Tyra Biosciences Receives IND Clearance From FDA To Proceed With Phase 2 Study Of TYRA-300
Brief: Tyra Biosciences Receives Ind Clearance From FDA To Proceed With Phase 2 Study Of Tyra-300 In Pediatric Achondroplasia (Beach301)
Brief: Tyra Biosciences Reports Interim Clinical Proof-Of-Concept Data For TYRA-300
BofA upgrades Tyra Biosciences to 'buy', raises PT